Grifols Q3 net profit rises 28% to EUR 162 million

By Public Technologies
  • Grifols’ third-quarter 2026 net profit climbed 28% year-over-year to EUR 162 million.
  • Revenue reached EUR 2.04 billion for the quarter, primarily driven by growth in Biopharma.
  • At September’s end, net leverage declined year-over-year to 3.98x, while liquidity increased to EUR 2.14 billion.
  • Egyptian operations remain on track to collect approximately one million liters of plasma in 2026.
  • Full-year 2026 guidance remains unchanged following nine-month performance in line with expectations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.